Objective: To describe anti-obesity bias in medical education including impact on patients, growth of biases over time, and education-based initiatives aimed at reducing bias.
Design: We reviewed available literature on anti-obesity bias in medical education and initiatives to address this bias.
Setting: Information from a wide variety of medical educational settings was included.
Participants: N/A RESULTS: Anti-obesity bias in healthcare is an independent risk factor for poor health outcomes and is pervasive throughout the culture of medicine. Medical students identify operating rooms as the number one location for anti-obesity comments, and students' biases increase throughout medical school. We propose several interventions (the 6 I's) as the next step in addressing this bias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jsurg.2022.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients.
Mayo Clin Proc
January 2025
Department of Surgery, Mayo Clinic, Jacksonville, FL.
Incretin-based obesity management medications (OMMs) fill a treatment gap in a stepped-care model between lifestyle change alone and metabolic bariatric surgery, resulting in weight loss of 15% to 20% of body weight. Public interest in and demand for OMMs has recently increased dramatically. Unfortunately, cost and access to OMMs remain a significant barrier for many patients.
View Article and Find Full Text PDFHealth and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.
Am J Lifestyle Med
November 2024
Wellcoaches Corporation, Wellesley, MA, USA (MM).
Glucagon-like peptide agonists (GLP-1) are highly effective anti-obesity medications. However, sustained effectiveness is potentially plagued by lack of adherence to the drug and resumption of pre-weight loss behaviors. Side effects are primarily severe gastrointestinal distress but can occasionally be more serious.
View Article and Find Full Text PDFThe anti-obesity effects of postbiotics: A systematic review of pre-clinical and clinical studies.
Clin Nutr ESPEN
December 2024
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- The study reviews the impact of postbiotics, a new category of compounds, on obesity, addressing the lack of systematic evidence in this area.
- Using databases like PubMed and SCOPUS, the researchers included 49 studies (9 human and 40 animal), highlighting the effectiveness of certain postbiotics in improving body composition and reducing obesity-related factors.
- The findings suggest that postbiotics may safely lower fat accumulation and enhance energy expenditure, but emphasize the need for more high-quality research to confirm these effects.
Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.
Arch Endocrinol Metab
October 2024
Divisão de Medicina Universidade Federal de Santa Catarina FlorianópolisSC Brasil Divisão de Medicina, Universidade Federal de Santa Catarina, Florianópolis, SC, Brasil.
The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
View Article and Find Full Text PDFPeptides Evaluated In Silico, In Vitro, and In Vivo as Therapeutic Tools for Obesity: A Systematic Review.
Int J Mol Sci
September 2024
Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
Bioinformatics has emerged as a valuable tool for screening drugs and understanding their effects. This systematic review aimed to evaluate whether in silico studies using anti-obesity peptides targeting therapeutic pathways for obesity, when subsequently evaluated in vitro and in vivo, demonstrated effects consistent with those predicted in the computational analysis. The review was framed by the question: "What peptides or proteins have been used to treat obesity in in silico studies?" and structured according to the acronym PECo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!